![Stephanie Tozzo](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stephanie Tozzo
Direttore Tecnico/Scientifico/R&S presso Avilar Therapeutics, Inc.
Patrimonio netto: - $ in data 30/06/2024
Posizioni attive di Stephanie Tozzo
Società | Posizione | Inizio | Fine |
---|---|---|---|
Avilar Therapeutics, Inc.
![]() Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Direttore Tecnico/Scientifico/R&S | 01/11/2021 | - |
Corporate Officer/Principal | 01/11/2021 | - |
Storia della carriera di Stephanie Tozzo
Precedenti posizioni note di Stephanie Tozzo
Società | Posizione | Inizio | Fine |
---|---|---|---|
COHBAR, INC. | Direttore/Membro del Consiglio | 11/07/2022 | 10/11/2023 |
Formazione di Stephanie Tozzo
Université Paris-Saclay | Graduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 3 |
Francia | 2 |
Posizioni
Director/Board Member | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Corporate Officer/Principal | 1 |
Settori
Health Technology | 2 |
Commercial Services | 2 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
COHBAR, INC. | Health Technology |
Aziende private | 1 |
---|---|
Avilar Therapeutics, Inc.
![]() Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Commercial Services |
- Borsa valori
- Insiders
- Stephanie Tozzo
- Esperienza